Calithera Biosciences, Inc.

Form 3

October 01, 2014

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB APPROVAL** 

**OMB** Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

**SECURITIES** Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

À Delphi Management Partners VIII, L.L.C.

2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Statement

(Month/Day/Year) 10/01/2014

Calithera Biosciences, Inc. [CALA]

(Last) (First) (Middle)

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting

\_X\_ Form filed by More than One

Filed(Month/Day/Year)

C/O DELPHI VENTURES.. 3000 SAND HILL ROAD, BLDG. 1, SUITE 135

(Street)

(Check all applicable)

Director \_\_X\_\_ 10% Owner Officer Other (give title below) (specify below)

MENLO PARK. CAÂ 94025

(City) (State) (Zip)

1. Title of Security (Instr. 4)

Table I - Non-Derivative Securities Beneficially Owned

2. Amount of Securities Beneficially Owned

(Instr. 4)

3. Ownership Form:

4. Nature of Indirect Beneficial

Reporting Person

Person

Ownership (Instr. 5)

Direct (D) or Indirect (I) (Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of

information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

SEC 1473 (7-02)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)

**Expiration Date** (Month/Day/Year)

2. Date Exercisable and 3. Title and Amount of Securities Underlying **Derivative Security** (Instr. 4)

5. Conversion Ownership or Exercise Form of Price of Derivative

6. Nature of Indirect Beneficial Ownership

(Instr. 5)

Edgar Filing: Calithera Biosciences, Inc. - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Derivative Security	Security: Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	(1)	(1)	Common Stock	6,808	\$ <u>(1)</u>	I	Delphi Ventures VIII, L.P. (2)
Series A Preferred Stock	(1)	(1)	Common Stock	66	\$ <u>(1)</u>	I	Delphi BioInvestments VIII, L.P. (3)
Series B Preferred Stock	(1)	(1)	Common Stock	415,128	\$ <u>(1)</u>	I	Delphi Ventures VIII, L.P. (2)
Series B Preferred Stock	(1)	(1)	Common Stock	4,053	\$ <u>(1)</u>	I	Delphi BioInvestments VIII, L.P. (3)
Series C Preferred Stock	(1)	(1)	Common Stock	740,312	\$ <u>(1)</u>	I	Delphi Ventures VIII, L.P. (2)
Series C Preferred Stock	(1)	(1)	Common Stock	7,228	\$ <u>(1)</u>	I	Delphi BioInvestments VIII, L.P. (3)
Series D Preferred Stock	(1)	(1)	Common Stock	745,825	\$ <u>(1)</u>	I	Delphi Ventures VIII, L.P. (2)
Series D Preferred Stock	(1)	(1)	Common Stock	7,282	\$ <u>(1)</u>	I	Delphi BioInvestments VIII, L.P. (3)

# **Reporting Owners**

Reporting Owner Name / Address	Relationships				
	Director	10% Owner	Officer	Other	
Delphi Management Partners VIII, L.L.C. C/O DELPHI VENTURES, 3000 SAND HILL ROAD, BLDG. 1, SUITE 135 MENLO PARK, CA 94025	Â	ÂX	Â	Â	
DELPHI VENTURES VIII LP 3000 SAND HILL RD. BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	ÂX	Â	Â	
Delphi BioInvestments VIII LP 3000 SAND HILL RD. BLDG 1, SUITE 135 MENLO PARK, CA 94025	Â	ÂX	Â	Â	
ROEDER DOUGLAS A C/O DELPHI VENTURES	Â	ÂX	Â	Â	

Reporting Owners 2

3000 SAND HILL RD., BLDG 1, SUITE 135 MENLO PARK, CAÂ 94025

DOUGLASS DAVID L C/O DELPHI VENTURES

3000 SAND HILL RD., BLDG 1, SUITE 135 Â Â X Â Â

MENLO PARK, CAÂ 94025

BOCHNOWSKI JAMES J C/O DELPHI VENTURES

3000 SAND HILL RD., BLDG 1, SUITE 135 Â Â X Â Â

MENLO PARK, CAÂ 94025

PAKIANATHAN DEEPIKA C/O DELPHI VENTURES

3000 SAND HILL ROAD, BLDG. 1, SUITE 135 Â X Â X Â Â

MENLO PARK, Â CAÂ 94025

## **Signatures**

By:/s/ Matthew T. Potter, Name: Matthew T. Potter, Attorney-in-Fact for:Delphi Management Partners VIII, L.L.C.,Delphi Ventures VIII, L.P., Delphi BioInvestments VIII, L.P., Deepika R. Pakianathan, Douglas A. Roder, David L. Douglass and James J.Bochnowski

10/01/2014

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The preferred stock is convertible at any time, at the holder's election, and has no expiration date. The preferred stock will automatically convert into common stock on a 1-to-1 basis upon closing of the initial public offering of the issuer.
  - The reported securities are directly owned by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. ("DMP VIII") is the general partner of DV VIII and may be deemed to have sole voting and dispositive power over the securities held by DV
- (2) VIII. Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DV VIII. Such persons and entities disclaim beneficial ownership of the securities held by DV VIII, except to the extent of any pecuniary interest therein.
  - The reported securities are directly owned by Delphi BioInvestments VIII, L.P. ("DBI VIII"). DMP VIII is the general partner of DBI VIII and may be deemed to have sole voting and dispositive power over the securities held by DBI VIII. Douglas A. Roeder, James J.
- (3) Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D. are the managing members of DMP VIII and may be deemed to share voting and dispositive power over the securities held by DBI VIII. Such persons and entities disclaim beneficial ownership of the securities held by DBI VIII, except to the extent of any pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3